BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Merck

Moderna

Pfizer

COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.

COVID-19 Vaccines Are on the Way and Major Players Are Cashing In

The vaccine will begin to be available to the public next week, says the government.

Pfizer and BioNTech's Coronavirus Vaccine Approved for Use in the U.K.

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate becomes the first-ever vaccine to get authorization.

Pfizer/BioNTech's COVID-19 Vaccine Gets Approval in U.K.

Encouraging News on COVID-19 Vaccine

Vaccine hopes are starting to be fulfilled as the first COVID-19 vaccine gets authorized.

Pfizer/BioNTech COVID-19 Vaccine Approved in the U.K.

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.

Pfizer/BioNTech Seek Marketing Nod for COVID-19 Vaccine in EU

Pfizer is seeking full marketing authorisation from Britain for its COVID-19 vaccine, an executive said on Wednesday as the U.S. drugmaker gears up to deliver by the weekend the first shots following approval for emergency use in the country.

Pfizer-BioNTech seeks full marketing approval from UK for COVID-19 vaccine

AstraZeneca

Johnson & Johnson

Moderna (MRNA), and Pfizer (PFE)/BioNTech (BNTX) file for emergency use authorization of their COVID-19 vaccine candidates in Europe

Will Americans Get COVID-19 Vaccine Sooner Than Europeans?

The UK became the first country in the world on Tuesday to grant emergency use authorization to Pfizer and BioNTech's COVID-19 vaccine. The vaccine, which demonstrated an efficacy rate of 95% in preventing COVID-19 among patients, will be made available to the country next week for a rollout to hospitals and vaccination centers across the country.

Pfizer surges 5% on emergency UK approval for COVID-19 vaccine (PFE)

Hi, The UK has approved Pfizer and BioNTech's coronavirus vaccine, becoming the first Western country to give a vaccine an OK. The plan is to make the vaccine available next week. 

UK approves its first vaccine

Care home residents and people over the age of 80 will be among the first to receive the Pfizer-BioNTech COVID-19 vaccine, when the U.K. rollout starts next week.

Who will be first in line for the Pfizer-BioNTech COVID-19 vaccine?

Senior citizens will be first in line as the UK is the first country to approve Pfizer's vaccine.

Pfizer Covid-19 vaccine approved for use in UK

The U.K.'s regulator had been delegated much of the work to authorize Europe's medicines, and seemed better prepared than most to approve the vaccine.

How the U.K. became first to approve the Pfizer-BioNTech vaccine, and are there dangers authorizing so fast?

The UK has approved Pfizer and its German partner BioNTech's COVID-19 vaccine — but regulators in the US are yet to make a decision on authorization. The UK's vaccine regulator approved the shot Wednesday morning, making it the first western country to authorize a COVID-19 vaccine. Vaccinations will start next week, the government said.

The UK has approved Pfizer and BioNTech's COVID-19 vaccine, but the US is still waiting. Here's why.

The U.K. has become the first country to approve the Pfizer-BioNTech Covid-19 vaccine, with preparations under way to begin the rollout next week.

U.K. Becomes First Country to Approve Pfizer's Covid-19 Vaccine

CureVac B.V

Novavax

Here's what you need to know about all of the leaders in the coronavirus vaccine race.

COVID Vaccine Stocks Update: Where Things Stand Now

The vaccine will be available across the U.K. starting next week with the elderly and frontline healthcare workers being the first to receive a shot.

U.K. Approves Pfizer-BioNTech's Covid-19 Vaccine, The First Country To Do So

U.K. becomes first country to approve a coronavirus vaccine, with immunisations to start within days for those most at risk

Pfizer and BioNTech's COVID-19 vaccine wins U.K. approval — rollout to begin next week

This is an historic moment. The beginning of the end of the pandemic.

Vaccine approval is a historic moment for the UK

The UK's medicines regulator has approved the BioNTech/Pfizer vaccine against COVID-19 for emergency use, the companies said today. The UK is the first country to approve the vaccine for widespread use — paving the way for some of the most “high risk” citizens, such as elderly care home residents, to get the jab before the end […]

The UK approves the BioNTech/Pfizer COVID-19 vaccine for emergency use

Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) said Wednesday they have received regulatory approval in the United Kingdom for their COVID-19 vaccine. What Happened: The go-ahead from the Medicines and Healthcare Products Regulatory Agency (MHRA) means the U.K. has become the first country to approve a COVID-19 vaccine on an emergency basis ahead of the United States and the European Union.

Pfizer-BioNTech COVID-19 Vaccine Gets UK Approval For Emergency Use

The UK has become the first Western country to officially have a new coronavirus vaccine, marking a potential exit route out of the pandemic. And it's happened in record time.   The vaccine developed by US drugmaker Pfizer and the small German biotech, BioNTech, can be used in the UK, after the independent regulatory body in the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) signed off the vaccine.

Regulator says yes to Pfizer and BioNTech: UK becomes first Western country to have a coronavirus vaccine

The U.K. has authorized the Pfizer/BioNtech coronavirus vaccine, making it the first country in the world to do so.

UK becomes first country to approve the Pfizer-BioNTech coronavirus vaccine for use

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19. This constitutes the first Emergency Use Authorization following a worldwide Phase 3 trial of a vaccine to help fight the pandemic. Pfizer and BioNTech are anticipating further regulat

Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19

The European Medicines Agency said Tuesday it has received conditional marketing approval applications from Pfizer Inc. (NYSE: PFE)-BioNTech SE – ADR (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA), the two frontrunners in the development of a coronavirus vaccine.  The decision isn't likely to come early, thereby pushing out the vaccine launch timeline.

News for BioNTech SE Stock (BNTX)